• GMP Consulting & Licensing Solutions
  • 1-647-234-9148
  • [email protected]
web-logoweb-logoweb-logoweb-logo
  • HOME
  • ABOUT US
  • SERVICES
    • Drug Establishment License
    • Medical Device Establishment License
    • GMP Training
    • Drug Identification Number
    • Standard Operating Procedures
    • Controlled Drugs and Substances
    • Qualification and Validation
    • Compliance Audits
    • Vendor and Supplier Audits
    • HACCP
    • Natural Health Products
    • Pharmacy and Medical Clinic Services
  • FAQs
  • INDUSTRY NEWS
  • CONTACT US
✕

List of Drugs for an Urgent Public Health Need

June 11, 2024

The List of Drugs for an Urgent Public Health Need includes the following details for each drug:

  • Brand Name
  • Medicinal Ingredient(s)
  • Route of Administration
  • Strength
  • Dosage Form
  • Identifying Code or Number, if assigned, in the country where the drug was authorized for sale.

Additionally, the List provides other information obtained through public health official notifications, such as:

  • Foreign Regulatory Authority that authorized the drug
  • Foreign Country from which the drug can be imported
  • Canadian Jurisdiction notifying for the drug (where the drug is allowed to be sold)
  • Urgent Public Health Need for the drug
  • Intended Use or Purpose of the drug in the Canadian jurisdiction
  • Date of Notification by a public health official.

A public health official notification allows a listed drug to be imported into Canada and sold in the notifying jurisdiction for one year. If the notification is not renewed within one year, the drug will no longer be eligible for importation and sale. The Minister also has the discretion to remove drugs from the List at any time.

List of Drugs for an Urgent Public Health Need

Brand NameMedicinal Ingredient(s)Dosage FormStrengthRoute of AdministrationForeign Identifying Code or NumberFor Information Purposes
PriftinRifapentineTablet150mgOral0088-2100-24FDA/USA Footnote1 Important foreign identified risk information-see footnote below First Nations and Inuit Health Branch / May 23, 2024 Tuberculosis crisis – For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease.
PriftinRifapentineTablet150mgOral0088-2102-24FDA/USA Footnote1 Important foreign identified risk information-see footnote below Public Health Agency of Canada – for use in all jurisdictions / February 20, 2024 Tuberculosis crisis – For the treatment of latent tuberculosis infection (LTBI) caused by Mycobacterium tuberculosis in combination with isoniazid in patients at high risk of progression to TB disease.

For full article, you can refer to the original post from Health Canada

Related posts

July 9, 2024

New version of Annex 2 to the Good manufacturing practices guide – Manufacture of biologics (GUI-0027)


Read more

Opening hours


Monday - Friday
09:00 AM - 06:00 PM
Weekend: Closed


LINKS


Home
About us
Services
FAQs
Industry News
Contact us

CONTACT


1-647-234-9148


If you have a question,
please contact at [email protected]

Privacy Policy | Terms & Conditions
© 2025 PHARMA 4U | All Rights Reserved